843 results on '"Sfakianos, John P."'
Search Results
2. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
3. Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
4. Thromboembolic Events After Robotic Radical Cystectomy: A Comparative Analysis of Extended and Limited Prophylaxis
5. Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer
6. Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy
7. Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer
8. Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology
9. Comparison of Perioperative Outcomes for Radical Nephrectomy Based on Surgical Approach for Masses Greater Than 10 cm
10. Contemporary outcomes of patients undergoing robotic-assisted radical cystectomy: A comparative analysis between intracorporeal ileal conduit and neobladder urinary diversions
11. Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review
12. Robot-Assisted Retroperitoneal Lymph Node Dissection (RPLND)
13. Complications of Robot-Assisted Radical Cystectomy
14. Infections After Adoption of Antibiogram-directed Prophylaxis and Intracorporeal Urinary Diversion for Robot-assisted Radical Cystectomy
15. The obesity paradox in metastatic castration-resistant prostate cancer
16. Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment
17. Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer.
18. Sexual health outcomes in sexual minority vs. heterosexual men after prostate radiotherapy.
19. PD02-07 POSITIVE CTDNA STATUS BEFORE RADICAL CYSTECTOMY PREDICTS LYMPH NODE STATUS AND PATHOLOGICAL UPSTAGING
20. MP61-20 UTILITY OF CIRCULATING TUMOR DNA IN PATIENTS WITH DIFFERENT STAGES OF TESTICULAR CANCER
21. PD38-07 90-DAY OUTCOMES COMPARING APIXABAN TO ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER ROBOTIC-ASSISTED RADICAL CYSTECTOMY
22. MP16-19 COMPARISON OF BCG TO GEMCITABINE/DOCETAXEL IN THE INTERMEDIATE RISK GROUP COMPOSED MOSTLY OF TAHG
23. PD38-01 NEGATIVE CTDNA STATUS PRIOR TO RADICAL CYSTECTOMY PREDICTS IMPROVED OUTCOMES
24. MP22-11 THROMBOEMBOLIC EVENTS AFTER ROBOTIC RADICAL CYSTECTOMY: A COMPARATIVE ANALYSIS OF EXTENDED AND LIMITED PROPHYLAXIS
25. Tips and tricks in achieving zero peri-operative opioid used in onco-urologic surgery
26. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
27. Natural killer cells: unlocking new treatments for bladder cancer
28. Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial
29. Imaging and Interventional Diversion Techniques for Bladder and Ureteral Conditions
30. POSITIVE CTDNA STATUS BEFORE RADICAL CYSTECTOMY PREDICTS POOR OUTCOMES
31. UTILITY OF CIRCULATING TUMOR DNA STATUS IN PATIENTS WITH DIFFERENT STAGES OF TESTICULAR CANCER
32. INFECTIONS AFTER ADOPTION OF ANTIBIOGRAM-DIRECTED PROPHYLAXIS AND INTRACORPOREAL URINARY DIVERSION FOR ROBOTIC-ASSISTED RADICAL CYSTECTOMY
33. GEMCITABINE AND DOCETAXEL INDUCTION ONLY VERSUS INDUCTION WITH MAINTENANCE IN LOW-RISK AND INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
34. BCG INDUCTION WITH GEMCITABINE/DOCETAXEL MAINTENANCE VS. GEMCITABINE/DOCETAXEL INDUCTION AND MAINTENANCE AS ADJUVANT THERAPY IN NON-MUSCLE INVASIVE BLADDER CANCER
35. BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
36. Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data
37. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy
38. Eliminating the routine use of postoperative drain placement in patients undergoing robotic-assisted radical cystectomy with intracorporeal urinary diversion
39. The impact of a rectal hydrogel spacer on dosimetric and toxicity outcomes among patients undergoing combination therapy with external beam radiotherapy and low-dose-rate brachytherapy
40. Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions
41. Harnessing Natural Killer Cell Function for Genitourinary Cancers
42. Role of the Innate Immune System in the Development, Progression, and Therapeutic Response of Bladder Cancer
43. Prolonged hormonal therapy and external beam radiation independently increase the risk of Persistent Hypogonadism in men treated with prostate brachytherapy
44. A multidisciplinary discussion of BladderPath
45. Molecular tracing of prostate cancer lethality
46. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study
47. Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
48. Involving Patients in the Development and Evaluation of an Educational and Training Experiential Intervention (ETEI) to Improve Muscle Invasive Bladder Cancer Treatment Decision-making and Post-operative Self-care: a Mixed Methods Approach
49. A multi-institutional analysis of 263 hilar tumors during robot-assisted partial nephrectomy
50. Current Role of Checkpoint Inhibitors in Urologic Cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.